STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Medivir AB
(Nasdaq Stockholm: MVIR) today announced that IGM
Biosciences, Inc. has initiated its clinical study in solid cancers
with birinapant (a k a IGM-9427) in combination with IGM's DR5
agonist antibody IGM-8444 (NCT04553692).
The combination of IGM-8444 and birinapant has previously shown
to enhance anti-tumor activity preclinically. The purpose of
this first clinical trial with the combination will be to explore
safety and tolerability.
In January 2021, Medivir entered
into an exclusive licensing agreement through which IGM Biosciences
received global, exclusive development rights for birinapant. Upon
signing the agreement, Medivir received USD
1 million, which will now be followed by an additional
USD 1.5 million as birinapant is
included by IGM Biosciences in clinical phase I studies.
"We are very happy with this important development step in the
clinical evaluation of birinapant's potential within oncology in
combination with IGM's antibody IGM-8444" says Magnus Christensen, interim CEO in Medivir.
For further information, please contact:
Magnus Christensen, Interim CEO,
CFO, Medivir AB
Phone: +46 (0)8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir AB is obliged to make this information public pursuant
to the EU Market Abuse Regulation.
The information was submitted for publication, through the
agency of the contact person set out above, at 15.00 CET on
November 4, 2021.
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/birinapant-clinical-study-initiated-by-igm-biosciences,c3447452
The following files are available for download:
|
https://mb.cision.com/Main/652/3447452/1491619.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/birinapant-clinical-study-initiated-by-igm-biosciences-301416698.html
SOURCE Medivir
